(VIANEWS) – KITRON (KIT.OL), REACH SUBSEA (REACH.OL), ITERA (ITERA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. KITRON (KIT.OL)
21.6% sales growth and 29.87% return on equity
Kitron ASA operates as an electronics manufacturing services company in Norway, Sweden, rest of Europe, the United States, and internationally. It manufactures electronics that are embedded in the customers' products; and box-built electronic products. The company's services include development services, such as product development, product management, and re-engineering services; and industrialization services, including prototype manufacturing, evaluation of new products, component engineering and database, test development, design and build of high level assembly lines, and environmental durability testing. Its services also comprise sourcing and procurement services; manufacturing, assembling, and testing of electronic products for the professional market; redesign, repair, and maintenance; and logistics and distribution services. The company was incorporated in 1996 and is headquartered in Billingstad, Norway.
Earnings Per Share
As for profitability, KITRON has a trailing twelve months EPS of kr2.8.
PE Ratio
KITRON has a trailing twelve months price to earnings ratio of 11.38. Meaning, the purchaser of the share is investing kr11.38 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.87%.
More news about KITRON.
2. REACH SUBSEA (REACH.OL)
19.4% sales growth and 26.05% return on equity
Reach Subsea ASA provides subsea services in Norway and internationally. It operates in two segments, Oil & Gas and Renewable/Other. The company offers inspection, maintenance, and repair services, such as structural inspections, WROV operation, SCM changeout, scale squeeze operations, water injection, ready for operation, subsea equipment maintenance, repair, commissioning, and boulder clearance; and construction support services, including seabed intervention, boulder clearance, touchdown monitoring, and pre-lay and post- lay survey, as well as vessel, remotely operated vehicles, personnel, survey, and on demand engineering. It also provides asset integrity/pipeline inspection, and engineering and project management services; reach remote services comprising survey, inspection, and IMR and seabed intervention; seabed survey services consisting of site surveys and geohazard investigation, pipeline inspection, seabed mapping, UXO, general, and route surveys; offshore cable; marine construction; and rig and mooring services. In addition, the company offers geophysical monitoring services, which include 4D gravity, seafloor subsidence monitoring, depth watch for seismic nodes, injection integrity monitoring, well drilling, and real time seismic monitoring services; and environmental monitoring services that comprise earthquake monitoring and prediction, C02 storage, and geothermal energy exploitation. It serves oil and gas, renewables, and utilities sectors. The company was formerly known as Transit Invest ASA and changed its name to Reach Subsea ASA in December 2012. Reach Subsea ASA was incorporated in 1909 and is headquartered in Haugesund, Norway.
Earnings Per Share
As for profitability, REACH SUBSEA has a trailing twelve months EPS of kr0.63.
PE Ratio
REACH SUBSEA has a trailing twelve months price to earnings ratio of 7.02. Meaning, the purchaser of the share is investing kr7.02 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.05%.
More news about REACH SUBSEA.
3. ITERA (ITERA.OL)
12.4% sales growth and 86.07% return on equity
Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.
Earnings Per Share
As for profitability, ITERA has a trailing twelve months EPS of kr0.76.
PE Ratio
ITERA has a trailing twelve months price to earnings ratio of 15.53. Meaning, the purchaser of the share is investing kr15.53 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 86.07%.
More news about ITERA.
4. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 5.32% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 22.4. Meaning, the purchaser of the share is investing kr22.4 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.32%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
VISTIN PHARMA’s EBITDA is 43.61.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the current quarter and 6.6% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 54.7%, now sitting on 410.31M for the twelve trailing months.
More news about VISTIN PHARMA.
